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Objectives: Over the past two decades, there has been tremendous growth in research 
regarding bipolar disorder (BD) among children and adolescents (ie, pediatric BD 
[PBD]). The primary purpose of this article is to distill the extant literature, dispel myths 
or exaggerated assertions in the field, and disseminate clinically relevant findings.
Methods: An international group of experts completed a selective review of the litera-
ture, emphasizing areas of consensus, identifying limitations and gaps in the literature, 
and highlighting future directions to mitigate these gaps.
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1  | INTRODUCTION
Over the past two decades, there has been tremendous growth in the 
scientific literature regarding bipolar disorder (BD) among children and 
adolescents (ie, pediatric BD [PBD]) (Figure 1). The literature now con-
tains numerous gold- standard clinical trials of pharmacologic agents 
for mania, an increasing evidence base for adjunctive psychosocial 
treatments, several large- scale prospective clinical cohort studies, 
representative epidemiologic studies (particularly focused on adoles-
cents) with international representation, numerous neurocognitive and 
neuroimaging studies, and an accelerating number of biomarker stud-
ies. Despite the volume, quality, and international spectrum of avail-
able literature, and regardless of the general consensus about some of 
the field’s previously most divisive and controversial topics, there re-
mains a perspective in the popular press, other branches of medicine, 
and even within mental health that the field of PBD lacks evidence 
and is replete with controversy. Therefore, the primary purpose of this 
article is to distill the extant literature, dispel myths or exaggerated 
assertions in the field, and disseminate clinically relevant findings. In 
this paper, an international group of experts completed a selective re-
view of the extant literature (including PubMed and Web of Science/
PsycINFO searches, querying other databases or conference proceed-
ings and unpublished reports on an ad hoc basis), emphasizing areas of 
established findings and consensus, identifying limitations and gaps in 
the literature, and highlighting future directions to mitigate these gaps.
2  | EPIDEMIOLOGY
2.1 | Established findings and consensus
In community samples around the world, it is now well established that 
bipolar spectrum disorders—an umbrella that covers bipolar I disorder, 
bipolar II disorder, cyclothymic disorder [CycD], bipolar disorder not 
otherwise specified (NOS) and other specified bipolar and related dis-
orders (OS- BRD)—occur in youths. The update of a published meta- 
analysis of epidemiologic studies1 using an identical search strategy 
identified six new studies satisfying inclusion criteria. The update 
includes 17 studies (seven from the USA) with 31 443 youth aged 
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Results: Substantial, and increasingly international, research has accumulated regard-
ing the phenomenology, differential diagnosis, course, treatment, and neurobiology of 
PBD. Prior division around the role of irritability and of screening tools in diagnosis has 
largely abated. Gold- standard pharmacologic trials inform treatment of manic/mixed 
episodes, whereas fewer data address bipolar depression and maintenance/continua-
tion treatment. Adjunctive psychosocial treatment provides a forum for psychoeduca-
tion and targets primarily depressive symptoms. Numerous neurocognitive and 
neuroimaging studies, and increasing peripheral biomarker studies, largely converge 
with prior findings from adults with BD.
Conclusions: As data have accumulated and controversy has dissipated, the field has 
moved past existential questions about PBD toward defining and pursuing pressing 
clinical and scientific priorities that remain. The overall body of evidence supports the 
position that perceptions about marked international (US vs elsewhere) and develop-
mental (pediatric vs adult) differences have been overstated, although additional re-
search on these topics is warranted. Traction toward improved outcomes will be 
supported by continued emphasis on pathophysiology and novel therapeutics.
K E Y W O R D S
adolescent, bipolar disorder, child, pediatric, youth
F IGURE  1 Articles about pediatric bipolar disorder indexed in 
PubMed each year. Search terms were (“bipolar disorder” or mania or 
manic) and (child or adole* or pediatric or juvenile) [Colour figure can 
be viewed at wileyonlinelibrary.com]
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7- 21 years, 576 of whom met criteria for bipolar spectrum disorders.2-17 
The updated weighted average prevalence rate of bipolar spectrum 
disorders is 2.06% (95% confidence interval [CI] 1.44%- 2.95%).
There was substantial heterogeneity across studies, but it was not 
explained by year of data collection, lifetime prevalence (vs other time 
periods), or sex. Studies that included more adolescents had signifi-
cantly higher prevalence estimates. Differences in the definition of 
BD explained the largest portion of variance between studies. As ex-
pected, broader definitions (ie, including NOS or CycD) had the highest 
rates while narrow definitions (ie, BD- I and - II only) had lower rates, 
but even this was not a complete explanation. The weighted average 
prevalence of BD- I was 0.49% (95% CI 0.22%- 1.09%), with four of 12 
studies reporting no BD- I cases. Although there is no epidemiologic 
study on PBD in Asia, several studies from clinical samples reported 
that PBD is also prevalent in Asia.18-20
Community rates are not higher in the USA, nor do rates appear 
to be increasing over time. In contrast, billing and services data show 
a marked increase in rates of diagnoses in the USA over a 20- year pe-
riod.21,22 Differences in training, conceptualization of cases and insur-
ance demands appear more of a factor23 than underlying differences 
in prevalence.
In summary, PBD prevalence rates appear relatively stable 
across studies. PBD is more common than autism or schizophrenia 
and much less common than depression or attention deficit hyper-
activity disorder (ADHD) in the community; more data are available 
with post- pubertal samples, and they find higher rates than before 
puberty.24
2.2 | Limitations, gaps, and future directions
New epidemiologic studies need to systematically assess hypomania 
and mania and differentiate them from other non- mood psychopa-
thology. Even the newest epidemiologic data were collected at least 
10 years ago (range 1986- 2005), and fewer than 1% of indexed papers 
on pediatric epidemiology include data about BD.1 Documenting age 
of onset of the first mood episode of each type will be vital, with more 
studies including prepubertal children, to clarify onset and course. If de-
pression manifests first, it may not be clear that it is following a bipolar 
course until later. Onset age may be bimodal25,26 and American youth 
may be at higher risk for very early onset.27 Existing literature con-
founds age and informant effects: studies with older participants are 
less likely to include interviews of parents. Studies relying only on ret-
rospective self- report are likely to underestimate hypomania or mania, 
as people forget or minimize the events, whereas depression may be 
more salient. Using more consistent criteria across studies will reduce 
the largest source of variance identified in extant meta- analyses.
3  | INTERNATIONAL FINDINGS
3.1 | Established findings and consensus
Prior studies in adults suggested that, although BD occurs worldwide, 
there could be international differences in the clinical characteristics 
of BD, including age of onset, comorbidity, early adversity, and fa-
miliality.28,29 Although international differences in BD are less well 
studied in youth as compared to adults, there now are PBD data from 
multiple countries including Australia/New Zealand, Brazil, China, 
France, India, Italy, South Korea, Spain, the Netherlands, Turkey, and 
the UK.30 In addition to the epidemiologic studies reviewed above, 
international BD data now include phenomenological,19,31-33 co-
morbidity,19,34 longitudinal,35,36 treatment,37,38 neuroimaging and 
biomarker,39-41 and high- risk studies.42,43 Numerous commentaries 
discuss purported international differences in the prevalence of PBD, 
which may be attributable to including more subtypes,1 differences 
in the interview method,44 training,23,45 or the type of sample studied 
(predominantly manic, depressive, treatment- seeking or registry), or a 
combination of these.46
Some findings converge with US data. For example, Brazilian fam-
ilies with PBD also show lower positive regard and higher negative 
expressed emotion (EE) compared to control families.47 There are, 
however, examples of non- replication. In contrast to US data, a recent 
Brazilian imaging study did not find white matter microstructure dif-
ferences between PBD youth, healthy bipolar offspring and healthy 
controls,48 and parent report of youth mood symptoms showed much 
lower discriminative validity than parent report in other countries.49 
However, it is unclear whether this a true international difference or a 
difference owing to methodologic factors.
A recent study directly compared Dutch and US samples of off-
spring of parents with BD.50 Both projects used the Achenbach 
Child Behavior Checklist (CBCL)51 as well as similar semi- structured 
interviews (eg, the Kiddie Schedule for Affective Disorders and 
Schizophrenia).52 After controlling for age, rates of DSM- IV BD- I 
(2.2% in the US sample and 1.5% in the Dutch sample) and BD- II (2% 
and 1%, respectively) were similar. In contrast, other disorders were 
significantly more common in the US sample, including depressive 
disorders (13% vs 4% in the Dutch sample), anxiety disorders (31% vs 
9%, respectively), ADHD (22% vs 8%, respectively), and disruptive be-
havior disorder (19% vs 6%, respectively). CBCL Externalizing scores 
were higher in the US sample (mean + standard deviation 15.0 + 9.7 
vs 10.8 + 7.6, respectively, P = .03). However, Internalizing scores 
did not differ between samples (raw M ~ 15), despite higher rates of 
anxiety and depressive disorders in the US sample. In the US, fewer 
parents had BD- I, affected parents were younger at their own illness 
onset, parental substance abuse rates were higher, and rates of pa-
rental employment and youth living with both biological parents were 
lower. These stressors may have contributed to the greater rates of 
problems in the US sample. The differences also illustrate the impor-
tance of the psychopathology of the parent bipolar sample to under-
standing rates of offspring psychopathology. The internalizing findings 
also suggest that there could be differences in clinical interpretation 
of similar levels of pathology, even using semi- structured approaches.
3.2 | Limitations, gaps, and future directions
Future work needs to determine whether there are meaningful in-
ternational differences in the prevalence, phenomenology, course, 
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treatment, and biology of PBD. Translating scales into multiple lan-
guages and pursuing cross- cultural validation are accelerating progress 
by using consistent definitions,50 revealing considerable continuity in 
phenomenology.53 Combining data sets internationally would help 
calibrate definitions and examine common risk factors.
4  | CLINICAL CHARACTERISTICS, 
DIFFERENTIAL DIAGNOSES,  AND COURSE
4.1 | Established findings and consensus
4.1.1 | Clinical characteristics
Interest in BD phenotypes spans decades. Over 25 years ago, the 
issue of severe chronic irritability as part of the bipolar spectrum po-
larized the field; this issue is now largely resolved.46,54,55 With regard 
to symptom presentations, one position held that elation and/or gran-
diosity was required for a diagnosis of BD in youth.56 There now is 
substantial consensus that chronic irritability, regardless of explosive-
ness or severity, is not sufficient for a diagnosis of BD, in contrast with 
formulations that focused on rages or severe aggression.57 However, 
irritability is commonly present in youth with BD. Counting irritability 
as part of the diagnostic criteria for a manic or hypomanic episode re-
quires that the irritability either begins or significantly increases in in-
tensity in conjunction with the presence of accompanying manic (DSM 
Criterion B) symptoms. Thus, a youth with BPD may have chronic ir-
ritability, but the diagnosis would not be made based on that mood 
state.58-61 Although severe irritability and emotional dysregulation are 
not proxies for BD, they are also not mutually exclusive of episodic, 
DSM- adherent BD. Irritability that waxes and wanes spontaneously or 
in conjunction with other episodic changes in energy or sleep is much 
more suggestive of a mood disorder than other pathology.
While calls to include severe, chronic irritability as a developmental 
type of BD among youth have waned, substantial data have accrued 
concerning repeated brief discrete episodes of hypomania for less than 
4 days as part of the BD spectrum. As among adults,62 youth manifest 
CycD63 and episodic OS- BRD, as well as BD- I and BD- II. However, 
as described below, youth with brief but well- defined episodes of 
mania or hypomania are at very high risk to switch into BD- I or BD- II 
(particularly if they have a family history of BD),64 and they have as 
much psychosocial impairment, suicidality, comorbidity (eg, substance 
abuse), and family history of BD as those with BD- I.65 Less research 
has specifically addressed CycD, which is often subsumed within the 
BD- NOS category due to lack of operationalized criteria.1,63,66
Ultra- rapid or “ultradian” cycling also has been associated with pe-
diatric (as well as adult) BD.67 Although youth with BD, particularly 
younger children, often have more mood fluctuations than adults, it 
appears that “ultra- rapid cycles” describes mood fluctuation within an 
episode, and they are not themselves distinct episodes.68
Similar to adult BD, PBD has extensive comorbidity, both in repre-
sentative epidemiologic studies with largely untreated samples17,69,70 
and in clinical samples.71 With the exception of developmental dis-
orders like ADHD and autism spectrum disorders, the patterns of 
comorbidity are broadly consistent between youth and adult presenta-
tions.71,72 Apparent differences may partly reflect limited assessment 
of ADHD and autism spectrum disorders in adult samples rather than 
a true difference in comorbidities between these age groups, although 
some studies also suggest an association between ADHD and earlier 
age of onset of bipolar illness in adult samples.73,74 The presence of 
comorbid disorders worsens the course and outcome of PBD, indicat-
ing the need for their identification and treatment. When determining 
comorbid diagnoses, it is important not to “double- count” overlapping 
diagnostic symptoms (eg, hyperactivity in ADHD and irritability in 
multiple disorders), as this leads to artificially high rates of comorbid-
ity. Identifying discrete mood episodes and ensuring that overlapping 
symptoms are (i) over and above what can be expected from the in-
dividual’s baseline and (ii) concurrent with mood episodes helps dis-
entangle clinical presentations. Conversely, symptoms that persist in 
periods of euthymia suggest a non- mood etiology, and thus a “true” 
comorbidity. Finally, there is increasing evidence that medical comor-
bidity is relevant to PBD, both in terms of the association of physical 
health characteristics such as obesity with suicidality, neurocognition, 
and other markers of psychiatric symptom burden, and in terms of 
future premature cardiovascular disease.75-79 Medical comorbidity is 
closely related to both the mood symptoms and related lifestyle be-
haviors such as sedentary lifestyle and binge- eating in PBD.80,81
4.1.2 | Differential diagnosis
Diagnosing PBD requires changes in mood and behavior that are un-
characteristic of the individual and more extreme than developmentally 
appropriate, persist long enough to satisfy duration criteria, and have 
a clear impact on functioning. If comorbid disorders are present, mood 
symptoms need to be above and beyond the regular symptoms for the 
other disorder. For example, if symptoms of ADHD get worse episodi-
cally, and during these episodes the youth presents symptoms more 
specific to mania (eg, decreased need for sleep), a PBD diagnosis should 
be considered. Symptom sequence may help differentiate BD from 
some other disorders: a teen with BD might first experience symp-
toms of hypomania and depression and then begin using substances, in 
contrast to another teen who experimented with drugs first and then 
began showing irritability. However, it can be difficult to separate onset 
of a comorbid disorder from onset of manic/hypomanic symptoms.
Although the new and controversial DSM- 5 diagnosis of disruptive 
mood dysregulation disorder (DMDD) cannot formally be diagnosed 
if the youth has BD,82 the phenotype commonly overlaps with those 
of all BD subtypes60,83,84 as well as other conditions, particularly op-
positional defiant disorder (ODD).85,86 Thus, one must evaluate the 
potential presence of BD even if DMDD is identified, and vice versa. 
The reliability of DMDD diagnoses was low in the DSM- 5 field trials, 
suggesting that it may be challenging to accurately identify clinically.
4.1.3 | Course
Multiple longitudinal studies have prospectively followed cohorts 
of youths for 4 or more years. Consistent findings include (i) high 
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rates of progression from BD- NOS or CycD to BD- I or BD- II (eg, 
43%),64 particularly in youth with a family history of BD; (ii) high 
rates of recovery from episodes, particularly with treatment (eg, 
81.5%);87,88 (iii) high rates of recurrence of depression, hypomania, 
or mania (eg, 62.5%);64,87,89,90 and (iv) patterns of comorbidity91 and 
treatment response congruent with adult BD.92 The prodrome of 
BD- I or BD- II, often identified retrospectively in adult studies, com-
monly involves attenuated mood symptoms; and sleep disturbance 
may be a marker clinically (see reference for detailed discussion of 
prodrome).93
4.2 | Limitations, gaps, and future directions
Remaining controversies include whether ADHD might be a prodrome 
for BD. Some studies suggest that ADHD might be a prodrome,94,95 
although some used interviews that blurred the distinction between 
mood episodes and more chronic presentations.44 Longitudinal stud-
ies of ADHD cohorts tend to find no or only small increases in risk of 
BD.96 Adding the DMDD diagnosis to DSM- 5 created several gaps 
in terms of evidence- based assessment methods to differentiate 
DMDD from mood disorders, and lack of clarity regarding effective 
treatments. DMDD has its own definitional problems, as irritability 
includes both mood (often loses temper) and behavior (what happens 
when temper is lost).46 The next version of ICD will not add DMDD as 
a diagnosis, instead making a mood disturbance specifier for ODD.97 
Research needs to evaluate the relative effectiveness of psychosocial 
(eg, parent training; emotion regulation strategies) and pharmacologic 
interventions for DMDD.61,98 Longitudinal data also raise interesting 
questions about the possibility of remission of DMDD and bipolar dis-
orders,55,99 a topic that warrants further study.
5  | MEASUREMENT
5.1 | Established findings and consensus
There has been a large increase in the number of scales available and 
supported by data to measure different aspects of PBD. Myths ready 
for retirement include: (i) there is no validated rating scale or checklist 
for assessing manic symptoms in youth, (ii) a profile of scores on the 
CBCL51 can be used as a proxy for a diagnosis of PBD, and (iii) thinking 
in polarized terms about the value of a particular informant perspec-
tive in the evaluation of PBD (see Table 1). Common (and mistaken) 
beliefs include “teacher report is essential for confirming a diagnosis 
of mania,” vs “teacher report is useless in the evaluation of PBD”, or 
“parents’ perspective is always right” vs “parents’ perspective is hope-
lessly contaminated by their own mood or agenda.”
5.1.1 | Current state of assessment
The current generation of practitioners completed their training be-
fore the bulk of research on PBD was available. Consequently, agree-
ment between clinicians about the presence or absence of PBD in 
a particular case is poor.100,101 Agreement also tends to be worse 
around CycD and OS- BRD,23,102 which is unfortunate given that these 
may be more common than BD- I.1,66
5.1.2 | Cross- informant report on checklists
Multiple studies have evaluated parent, youth, and teacher report 
on both broad symptom checklists, such as the Achenbach System 
of Empirically Based Assessment,51 and manic symptom scales. 
Agreement between informants on ratings of the youth’s mood symp-
toms tends to be only “fair,” ie, in the r = .2 to .3 range, consistent 
with meta- analyses of agreement about youth mood and behavior in 
general.103
Checklists can detect cases needing more in- depth evaluation for 
potential PBD. A recent meta- analysis found 63 effect sizes—38 based 
on caregiver, 14 on youth, and 11 on teacher report, with eight check-
lists providing at least two different effect sizes. Teacher and youth 
reports had medium effect sizes, and parent/caregiver reports had 
the largest effect sizes. The Achenbach Externalizing Scale outper-
formed the putative “bipolar” profile, consistent with findings that the 
“bipolar” profile is not specific to PBD.104,105 Manic symptom scales 
fared better at identifying PBD, with three top tier options: The Parent 
General Behavior Inventory106 and its 10- item mania short form,107 
the Child Mania Rating Scale108 and its 10- item short form,109 and the 
parent version of the Mood Disorder Questionnaire.110
These scales are not accurate enough to justify their use as uni-
versal screening devices or as substitutes for a (semi- )structured 
diagnostic interview. However, they can change the probability of 
a PBD diagnosis within an evidence- based medicine or Bayesian 
decision- making framework111,112 and substantially improve the ac-
curacy of clinical interpretation and agreement about next clinical 
action.102,112 Some checklists have also shown sensitivity to treat-
ment effects in masked randomized controlled trials (RCTs), with ef-
fect sizes equal to those based on direct interview of the youth and 
primary caregiver.113,114 Checklists can improve diagnostic decision 
making in a range of clinical settings, as well as measuring treatment 
response.90,100-102
5.1.3 | Diagnostic and severity interviews
Semi- structured or structured diagnostic interviews that systemati-
cally evaluate mood symptoms remain the best available method to 
establish PBD diagnoses52,115 as well as symptom severity. The Young 
Mania Rating Scale (YMRS)116 and Child Depression Rating Scale 
Revised117 have been the industry standard interviews to quantify 
severity. Newer alternatives were designed for pediatric patients, 
with developmentally appropriate anchors and complete coverage of 
DSM mood symptoms.118 Psychometric differences between sever-
ity interviews are small,119,120 so the choice is more conceptual than 
statistical. Interview length and training requirements are barriers to 
routine clinical use.44 More structured methods are faster and easier 
to use consistently, and are surprisingly popular with patients.121 It 
is important to check for mood episodes in the context of develop-
mental history at the outset of the interview. Few methods provide a 
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TABLE  1 Summary of myths, consensus, and next actions for research on pediatric bipolar disorder
Area Myths Data Five- year needs
1. Epidemiology 1. Doesn’t happen in 
children
1. Evident in epidemiologic samples in ages 5 
years and higher
2. Convergent adolescent data
3. No difference in overall or BD-I/II rates
4. Inconsistent inclusion and/or definition of 
NOS/OS-BRD
1. Include full age range
2. Use consistent definition of BD spectrum 
(NOS and OS-BRD)
3. Examine BMI, pubertal status, and 
comorbidity
2.  International 
perspectives
1. No evidence outside 
of US
1. Evidence base includes multiple non-US studies 
covering assessment, genetics, treatment, 
imaging, outcome, and comorbidity
1. Ensure valid translation available in 
multiple languages
2. Move toward Kessler/Harvard/Michigan-
team model (WHO) using CIDI, to allow 
data integration and direct comparisons
3.  Clinical 
characteristics, 
differential 
diagnoses, 
and course
1. Adult criteria do not 
apply
2. Can forego the 
requirement for episodes
3. Predominantly chronic, 
and characterized by 
irritability without elation
1. Most youth have both irritability and elation 
at most severe episode
2. Applying adult criteria yields convergent 
findings with adult BD
3. Irritable-only (hypo)mania is uncommon but 
otherwise symptomatically similar to other 
types of PBD
4. Most research defines BD based on DSM, and 
requires episodes
1. Study ADHD and related neurocognitive 
profiles as indicators of risk for BD
2. Examine comorbid DMDD-type phenotype 
in terms of prognostication and treatment
4. Measurement 1. Screeners are not helpful
2. CBCL is sufficient
3. One type of informant 
is inherently superior 
(teacher, parent, or  
child)
1. Multiple published measures report high 
validity coefficients
2. CBCL is a poor proxy for diagnosis
3. Screeners can be part of evidence-based 
medicine approach to diagnosis, and inform 
next steps
1. Examine incremental value of biomarkers, 
imaging, and cognitive testing for 
diagnostic accuracy
2. Test measures in samples that allow 
meaningful comparison groups to BD (eg, 
ADHD and depression, rather than healthy 
controls)
5.  Course, 
outcome, and 
comorbidity
1. Chronic, non-episodic
2. No evidence of 
diagnostic continuity 
into adulthood
1. When defined based on episodicity, continues 
to evince episodicity prospectively
2. Comorbidity largely dependent on age
3. Comorbidity by late adolescence is similar to 
that in adulthood (higher rates of SUD and 
anxiety; lower rates of ADHD)
4. Overlapping symptoms of mania and ADHD 
should not be simply double counted
1. Include cognition, imaging, and biomarkers 
in prospective studies to inform staging 
models
2. Be consistent about hierarchical exclusions 
(CD vs ODD)
3. Examine DMDD with/without BD 
exclusions
6.  Pharmacologic 
treatment
1. SGAs effective
2. Youth extra-sensitive to metabolic side effects
3. Mood-stabilizers less efficacious than in adults
4. Stimulants for comorbid ADHD, in the context 
of a mood stabilizer, are usually safe and 
efficacious
5. Adjunctive nutritional interventions show promise
1. Determine if early stimulant or antidepres-
sant treatment for ADHD and depression/
anxiety, respectively, precipitates BD
2. Explore treatment for bipolar depression 
and maintenance
3. Study clinical staging using low-risk 
interventions for high-risk youth
7.  Psychosocial 
treatment
1. No validated treatments
2. Specific elements of 
treatment not relevant
1. Family psychoeducation plus skill building is a 
well-established category of psychotherapy
2. High EE predicts response to different 
treatments
1. Determine core components linked to 
positive outcome
2. Match patients to treatments based on EE, 
etc.
3. Develop novel methods to access 
psychotherapy content
4. Study dissemination and implementation 
strategies
8.  Imaging and 
neurocognition
1. No specific findings; 
overlap with ADHD/
ODD
1. Several distinguishing features, but also 
overlapping findings with SMD/ADHD
1. Complete larger, repeated-measures 
studies
2. Use multimodal imaging
9. Biomarkers 1. Few data 1. Increase uptake of biomarker research
2. Use multimethod research (eg, integrate 
imaging)
ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder; BMI, body mass index; CBCL, Achenbach Child Behavior Checklist; CD, conduct dis-
order; CIDI, Composite International Diagnostic Interview; DMDD, disruptive mood dysregulation disorder; EE, expressed emotion; NOS, not otherwise 
specified; PBD, pediatric bipolar disorder; ODD, oppositional defiant disorder; OS- BRD, other specified bipolar and related disorders; SGA, second- 
generation antipsychotic; SMD, severe mood dysregulation; WHO, World Health Organization.
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clear algorithm for CycD or OS- BRD—a key omission given the data 
on prevalence and burden.
5.1.4 | Risk factors as part of clinical evaluation
Risk factors inform the initial diagnostic evaluation process, and may 
guide treatment selection. Family history of mood disorders—and 
BD in particular—is the best- validated risk factor, recommended for 
routine clinical evaluation, while keeping in mind that the majority 
of youth with a family history will not necessarily develop BD. Brief 
screening tools make adding family history clinically feasible.122 High 
EE (ie, criticism, hostility, and emotional overinvolvement) and high 
family conflict are risk factors for treatment drop- out and more rapid 
relapse.90 High- EE families may show larger responses to family- 
focused psychotherapeutic interventions.123
5.2 | Limitations, gaps, and future directions
Although considerable advances have been made in the use of rat-
ing scales, checklists, and structured diagnostic interviews, little work 
has been done with neurocognitive or neuroimaging methods using 
clinically generalizable comparison groups to establish whether these 
methods have diagnostic specificity. Productive next steps in assess-
ment research would be to examine hybrid batteries that combine 
checklists and neurocognitive measures, biomarkers, or imaging to 
test incremental validity (ie, the degree to which each measure im-
proves diagnostic accuracy) in order to guide the most cost- effective 
test sequences. Better assessment of developmental phenomenology 
would be valuable to clarify prodromal presentations and trajectories. 
Structured interviews could be redesigned to better capture duration, 
potential prodrome, and trajectories. Rapid changes in Internet- based 
and smartphone delivery of clinical assessments need to be integrated 
with traditional assessment and treatment. Finally, feasibility, ac-
ceptability and utility of translation of research tools into real- world 
measurement- based care need to be studied.
6  | PHARMACOLOGIC TREATMENT
6.1 | Established findings and consensus
This section summarizes extant literature about pharmacologic treat-
ment of PBD, emphasizing RCTs. For additional detail, the reader is 
referred to recent reviews on this topic.37,124-129
6.1.1 | Manic/mixed episodes
Second- generation antipsychotics (SGAs) approved by the United 
States Food and Drug Administration (FDA) for the treatment of 
acute mania and/or mixed mania in children and adolescents (10- 
17 years) include risperidone, aripiprazole and quetiapine, olanzapine, 
and asenapine13-17 (http://www.accessdata.fda.gov/scripts/cder/
daf/). Lithium has FDA indication for the treatment and recurrence 
prevention of mania in youths aged 12 years and older, bolstered by 
a recently published positive 8- week RCT for youths 7- 17 years old 
with BD- I manic/mixed episodes.130 In that study, change in mania 
symptom scores was significantly larger in lithium- treated partici-
pants, as was global improvement at week 8, compared to placebo- 
treated participants.
A large (n = 153) 8- week National Institute of Mental Health (NIMH)- 
funded RCT compared lithium vs divalproex vs placebo in youths aged 
7- 17 years with BD- I mania.127 Participants randomized to divalproex 
had a significantly larger reduction in YMRS scores (ΔM = 8.3) from 
baseline compared to those randomized to placebo (ΔM = 5.3) (P = .04). 
There was not a statistically significant difference in YMRS scores for 
subjects randomized to lithium (7.2) compared to placebo (P = .19), or 
divalproex vs lithium (P = .35). However, another 4- week RCT of dival-
proex extended- release was negative when comparing an active group 
(n = 74) to placebo (n = 70).131 In this investigation, treatment with dival-
proex extended release (ER) promoted a mean reduction of 8.8 points in 
the YMRS, and the placebo group presented a mean reduction of mania 
of 7.9 points (P = .6). In an open extension of this trial with divalproex 
ER, where only 26 of 66 patients completed a 6- month follow- up, the 
mean YMRS score decreased by 2.2 points from a baseline of 20.3.
An early meta- analysis on the treatment of PBD (N = 2666 par-
ticipants across 46 trials) reported that SGAs were highly efficacious 
and superior to the modest anti- manic effects for traditional mood- 
stabilizing agents, such as lithium carbonate, divalproex sodium, and 
carbamazepine, when used as monotherapy.129 Another meta- analysis 
of double- masked placebo- controlled RCTs of treatment for BD- I 
mania among youth (n = 1609) and adults (n = 6501) found that SGAs 
were more efficacious but more metabolically burdensome compared 
to traditional mood stabilizers among youth, but showed no such dif-
ferences among adults.132 However, these meta- analyses predated 
recent studies supporting the efficacy of lithium.
The anticonvulsants divalproex sodium and carbamazepine have 
not fared well head- to- head with SGAs. In two meta- analyses, treat-
ment effect was less robust with anticonvulsants than with SGAs.105,106 
An RCT of divalproex extended release was negative,131 as was a large 
RCT of oxcarbazepine,110 and a topiramate RCT in youth was inter-
rupted prior to its completion due to negative results in adult studies; 
it failed to show efficacy in youth given inadequate power.133 A study 
of 10 outpatients with BD (11- 17 years old) whose weight increased 
by > 5% during treatment with mood- stabilizer or antipsychotic mono-
therapy were switched to topiramate; reductions in manic symptoms 
and weight were observed.133,134
In the “Treatment of Early Age Mania” 8- week trial, which included 
290 youths aged 6- 15 years with BD- I manic or mixed episodes, re-
sponse rates were 68% for risperidone, 35% for lithium, and 24% for 
divalproex sodium.135 The advantage of risperidone vs lithium was 
greater for youth with ADHD (vs non- ADHD) and non- obese (vs obese) 
youth.136 However, rates of comorbid ADHD in this study were > 90%, 
limiting power for ADHD vs no- ADHD comparisons, and some sites 
showed similar response rates for risperidone and lithium. Concerns 
have been raised regarding several characteristics in this sample, in-
cluding prolonged episodes, very early childhood onset, and high rates 
of rapid cycling, constraining comparisons with adult studies.137
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6.1.2 | Bipolar depression
The combination of olanzapine and fluoxetine has an FDA indication 
for BD depression in youth aged 10- 17 years old.138 In a recently pre-
sented RCT of 347 youth 10–17 years old, lurasidone was associated 
with significantly greater improvement in depression symptoms at 6 
weeks as compared to placebo (effect size, 0.45). 139 There have been 
two negative RCTs of quetiapine for bipolar depression.140,141 In a 
sample of 193 adolescents (10- 17 years old) with BD- I or BD- II who 
received quetiapine or placebo for 8 weeks, although nonsignificant 
differences were observed between the responses in the placebo and 
quetiapine groups (P = .63), high rates of response were observed in 
both groups (placebo: 55%, and quetiapine ER: 63%).127 A smaller trial 
of 32 adolescents (12- 18 years old) with BD- I where subjects were 
randomized for 8 weeks to placebo (n = 15) or quetiapine (n = 17) 
revealed no statistically significant differences in response rates be-
tween the placebo (67%) and quetiapine (71%) groups.128 Positive 
preliminary open trials142,143 or chart reviews144 of lithium and lamo-
trigine warrant future RCTs. However, high placebo response rates in 
depression studies require larger samples than mania trials or blinded 
placebo lead- in. Although the precise frequency of antidepressant- 
induced mania is uncertain,145,146 practice parameters and guidelines 
suggest avoiding antidepressant monotherapy; this approach is sup-
ported by pharmaco- epidemiologic data.147
6.1.3 | Maintenance/continuation treatment
There have been few maintenance/continuation treatment studies 
in youth, most of which have been previously reviewed.125 An early 
observational study of continuation treatment with lithium found an 
increased risk of relapse among adolescents who were not treated 
with lithium following hospitalization for mania.148 A subsequent 
study of children and adolescents with BD who had been stabilized 
on the combination of lithium and divalproex found a similar survival 
time to recurrence among those randomized to continuation treat-
ment with monotherapy with lithium or divalproex.149 In a larger con-
tinuation study of 226 youth with BD (mean duration 124.4 days), 
YMRS scores decreased a further 12.4 points.150 In a 72- week main-
tenance study, 96 outpatient children, 4- 9 years old, with PBD who 
had been stabilized on aripiprazole (mean dose 6.4 mg) were rand-
omized to continuation with aripiprazole or placebo (n = 30/group).151 
Although children randomized to aripiprazole, vs placebo, were en-
rolled significantly longer until time to discontinuation for a mood 
event or for any reason, the study was constrained by high drop- out 
rates within the first 4 weeks (50% for the aripiprazole group; 90% 
for the placebo group), understood by the authors as a nocebo effect. 
No significant between- group treatment effects on symptom rating or 
changes over time were observed for mania, depression, general im-
pression, or global assessment. Another placebo- controlled continua-
tion study of aripiprazole (10 mg or 30 mg) in youths (10- 17 years old) 
with manic/mixed episodes followed participants for 26 weeks under 
double- blind conditions after a 4- week acute treatment phase.152 For 
both aripiprazole dosages, there were greater reductions in YMRS 
symptoms (in last observation carried forward analyses only) and time 
to all- cause discontinuation was longer for both aripiprazole dosages 
compared to placebo. There were also higher response rates, greater 
improvements in global functioning, and greater reductions in clinical 
global impression bipolar severity for each of the aripiprazole groups 
vs placebo. Another recent study of 301 children and adolescents 
with BD- I stabilized for at least 6 weeks on adjunctive lamotrigine, in 
combination with up to two mood stabilizers or antipsychotics, ran-
domized participants to 36 weeks of either continuation treatment 
with lamotrigine or placebo.153 Although the primary analysis was 
negative, continuation with lamotrigine was superior to placebo (haz-
ard ratio 0.46) in 13- 17- year- olds, but not in 10- 12- year- olds (haz-
ard ratio 0.94). Although reasons for this discrepancy are uncertain, 
it may relate to higher rates of ADHD in the younger group. Finally, 
a 50- week open- label, flexible- dose extension study of 321 youth, 
10- 17 years old, with BD- I (lead- in study treatment: placebo, n = 80; 
asenapine, n = 241) reported that: (i) there was a mean 9.2- point re-
duction in YMRS at week 50; (ii) 79.2% were considered responders 
based on 50% reduction in YMRS relative to acute trial baseline; (iii) 
somnolence/sedation/hypersomnia (42.4%) and significant weight 
gain (34.8%) were very common.154
6.1.4 | Comorbidity
Positive results have been reported regarding the treatment of co-
morbid ADHD with mixed amphetamine salts and methylphenidate, 
albeit in modest- sized samples, particularly in euthymic youth.37,155,156 
Aripiprazole did not differ from placebo in ADHD symptom reduc-
tion.157 Preliminary findings from open trials and case reports suggest 
promise for adjunctive atomoxetine.158 Although stimulants, as well 
as antidepressants, hold some risk of precipitating mania, precise es-
timates of this risk are lacking, both with and without ongoing mood 
stabilizer cotreatment.145 A single small RCT found that lithium im-
proved mood symptoms and comorbid substance use disorder among 
adolescents with, or at risk for, BD.159
6.1.5 | Nutritional interventions
Four open- label nutritional trials, three of Omega 3 (Ω3) monotherapy 
(n = 3) and one of a commercially available multinutrient, in youth with 
BPSD provide preliminary evidence of potential benefits in terms of 
manic and depressive symptoms, global functioning, and parent- rated 
internalizing and externalizing behaviors.160-162 A 12- week pilot RCT 
(N = 23 youth with BD- NOS or CycD) found that the combination of 
Ω3 and psychoeducation was superior to placebo and active monitor-
ing.163 An RCT of flax seed oil (alpha- linolenic acid [ALA]) in youth 
with BD- I/BD- II was negative.164
6.2 | Limitations, gaps, and future directions
Positive RCTs for maintenance treatment and bipolar depression 
are lacking, although preliminary positive open trials hold prom-
ise. Pharmacologic treatment of comorbidities other than ADHD 
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is another gap. Given concerns about heterogeneity of longitudinal 
course, it would be helpful to examine whether subtype of BD or age 
of onset moderates treatment response. Future studies should include 
neuroimaging, neurocognition, and peripheral biomarkers as modera-
tors and predictors of treatment response. Large- scale RCTs of nu-
tritional interventions are warranted, based on positive pilot RCTs 
and open- label trials. Studies concentrating on CycD and OS- BRD are 
crucial to address the need for titrated and evidence- based options, 
along with more masked maintenance studies to look at altering tra-
jectories, and head- to- head trials and trials of combinations with non- 
pharmacologic treatments. Although systematically addressing the 
topic of offspring of parents with BD was beyond the scope of this 
article, it is important to note that there is also a need for large- scale 
RCTs examining the relative efficacy, tolerability, and safety of anti-
depressants vs mood stabilizers for anxiety and/or depression, and 
the efficacy, tolerability, and safety of stimulants for ADHD, among 
BD offspring.
7  | PSYCHOSOCIAL TREATMENTS
7.1 | Established findings and consensus
Adult psychotherapy trials provide substantial evidence for the ef-
fectiveness of family- focused therapy (FFT),165 group psychoe-
ducation,166-168 and interpersonal and social rhythm therapy169 in 
improving symptoms, reducing rates of recurrence, and hastening 
recovery in adults with BD. In recent years, an accumulating body of 
evidence similarly supports the use of manualized psychotherapies for 
the treatment of PBD. A recent review highlighted 13 unique stud-
ies170 and three studies published since that review further strengthen 
the evidence base,171-174 whereas one additional study offers mixed 
evidence.175 The category of family psychoeducation plus skill build-
ing can be considered as a well-established treatment, meaning that 
two or more research groups have, via independent RCTs, demon-
strated efficacy.176 Dialectical behavior therapy171 can be considered 
possibly efficacious, based on a single RCT or multiple studies by the 
same group, while interpersonal and social rhythm therapy177 remains 
experimental in youths at this time. Effectiveness trials suggest that 
family psychoeducation plus skill- building approaches have excellent 
acceptability and sustainability in community settings.178,179
Treatment mediator analyses suggest that psychoeducation leads 
families to improve the quality of services they utilize, mediated by pa-
rental treatment beliefs; improved quality of services, in turn, mediates 
improved outcomes.180 Improved parenting skills and coping, family 
flexibility and family positive reframing are linked to improved mood 
and global functioning in youth with PBD.181 Treatment moderators 
include youth impairment182 and family EE,123 along with comorbid 
disorders, youth age, and family socioeconomic status (SES). Predictors 
of better treatment response include greater impairment, more stress/
trauma history for the child, less Cluster B personality symptoms in 
parents,182 and comorbid anxiety disorders.131
With regard to secondary outcomes other than mood, family psy-
choeducation plus skill building are also associated with a reduction 
in behavioral symptoms.183 In an open trial of an adaptation of family 
psychoeducation and skill building, benefits were observed for ad-
olescents with BD and comorbid substance use disorders.184 While 
no dismantling studies have been conducted, therapeutic ingredients 
common to the psychotherapy category family psychoeducation and 
skill building should be used. These include family involvement; psy-
choeducation about etiology, symptoms, course, medications, risk and 
protective factors, and effective treatment of BD; skill building (espe-
cially communication, problem- solving, and emotion regulation skills); 
and relapse and recurrence prevention.170
In regard to prevention, or delay of onset, two RCTs have examined 
the impact of family psychoeducation plus skill building in youth at 
high risk for developing BD. Youth who received FFT had more rapid 
recovery from their initial mood symptoms, experienced more weeks 
in remission, and had lower YMRS scores over 1 year compared to 
youth who received enhanced care.185 In a second study, youth with 
depression and transient manic symptoms were 4 times less likely to 
convert to BPSD at 12- month follow- up if they received multi- family 
psychoeducational psychotherapy plus treatment as usual (TAU) com-
pared to the group who received only TAU.186
7.2 | Limitations, gaps, and future directions
More work is needed to (i) determine the impact of low- risk inter-
ventions (eg, psychosocial treatments and nutritional interventions) in 
preventing or delaying the onset of BD in high- risk youth; (ii) test psy-
chotherapies in diverse populations, including different SES and cul-
tural backgrounds; (iii) determine what modifications are appropriate 
based on age or treatment format (eg, group or individual/family); (iv) 
determine the impact of psychotherapy on functional and quality of 
life outcomes as well as symptoms; (v) develop efficient ways to train 
large numbers of clinicians in these treatments; (vi) identify mecha-
nisms of change and essential treatment components;170 (vii) examine 
the potential benefits of smartphone or Internet- based delivery; (viii) 
evaluate combinations of pharmacotherapy and psychotherapy; and 
(ix) determine how best to disseminate manual- based psychothera-
pies into health care settings.
8  | NEUROIMAGING AND 
NEUROCOGNITION
8.1 | Established findings and consensus
Prevailing pathophysiologic models of BD implicate abnormalities in 
brain regions that regulate emotion and attention, namely the emo-
tional control network (ECN).187 The ECN is comprised of ventrolateral 
and ventromedial prefrontal networks, which modulate the limbic sys-
tem, specifically the amygdala, in conjunction with subcortical nuclei, 
such as the thalamus and striatum.187,188 Increasing evidence suggests 
that there are anatomical, neurochemical, functional and cognitive ab-
normalities within the ECN in PBD.188,189 Pathophysiologic abnormali-
ties underlying other cognitive functions that are altered in BD, such 
as reward processing, have also been studied.190
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8.1.1 | Neuroimaging
Brain structure
Within the ECN, the amygdala plays a central role in emotional regula-
tion. Two meta- analyses of magnetic resonance imaging (MRI) studies 
reported that youth with PBD present with smaller amygdala volumes 
compared with controls.191,192 One prospective study that evaluated 
youth after their first manic episode showed that amygdala volumes 
failed to show a normal increase with aging in patients, whereas this 
did not occur in controls or in youth with ADHD, suggesting that ham-
pered neurodevelopment of the amygdala may underlie the dysfunc-
tional emotional processing present in the ventral- limbic pathway.193 
Diffusion tensor imaging (DTI) studies have investigated abnormalities 
in the white matter microstructure of youth with PBD. Preliminary 
findings suggest the presence of abnormal white matter microstruc-
ture in superior frontal regions,194,195 and inferior/ventral frontal 
areas, such as the orbitofrontal or anterior cingulate cortex, and ante-
rior regions of the corpus callosum196-200 compared to controls. One 
study found even greater reduction in white matter integrity in the 
anterior limb of the internal capsule in PBD vs adult BD.201 Most of 
these studies had very small sample sizes, but, together, they are con-
sistent with a hypothesis of structural connectivity deficits between 
prefrontal- subcortical areas that underlie the prefrontal- limbic dys-
function in PBD.
Brain function
Meta- analyses of over 20 task- based functional MRI (fMRI) stud-
ies with approximately 500 youth concluded that BD involves 
hypoactivation of prefrontal areas and hyperactivation of limbic 
areas.202,203 Weigbreit et al (2014) included more emotional (emo-
tional face processing) than non- emotional (or cognitive) tasks 
whereas Lee et al (2014) did not discriminate the effects of emo-
tional vs cognitive tasks. PBD presents with greater activation in 
the right amygdala, parahippocampal gyrus, and left putamen, and 
lower activation in the right ventrolateral and dorsolateral prefron-
tal cortices compared with controls in paradigms that involve emo-
tional stimuli.202,203 These findings suggest that prefrontal regions 
are unable to modulate hyperactive limbic regions,203 due either 
to a primary prefrontal dysfunction or to altered connectivity be-
tween prefrontal and limbic regions. Studies using non- emotional 
tasks (eg, reversal learning and reward anticipation) also showed 
abnormal functional activity of prefrontal areas, such as the dor-
solateral prefrontal cortex, parietal regions, such as the temporal 
gyrus, and subcortical regions, such as the thalamus, during pro-
cessing of the tasks.204-206 fMRI studies using tasks of attention and 
response inhibition have also found that prefrontal areas involved 
in attention and inhibitory control (namely the ventrolateral pre-
frontal cortex) are hypoactive while processing a continuous per-
formance task in patients with PBD and comorbid ADHD, while 
posterior parietal and temporal areas are hyperactive, possibly as a 
compensatory mechanism.207 Other studies using continuous per-
formance task and response inhibition also have found underacti-
vation of the ventrolateral prefrontal cortex.208,209 The few resting 
state fMRI studies in PBD show that youth with PBD present with 
fronto- temporal, amygdala- hippocampus and amygdala- precuneus 
functional connectivity alterations,210-212 with similar alterations 
observed during bipolar depression.213 Together, these studies 
suggest that PBD is characterized by abnormal prefrontal- limbic 
functional connectivity in the processing of emotion, attention, 
and reward. Although still too preliminary to allow any definitive 
conclusions about the neurophysiology of PBD, these findings con-
verge with adult BD findings.
Brain chemistry
Proton magnetic resonance spectroscopy studies are particularly im-
portant to help understand two current neurobiological hypotheses 
of BD, ie, glutamatergic dysfunction and mitochondrial dysfunction or 
energy metabolism dysfunction. Several studies in PBD have shown 
abnormalities in glutamate or glutamine levels in prefrontal brain 
areas.214,215 Abnormal levels of metabolites that are considered to be 
biomarkers of mitochondrial dysfunction or cell energy metabolism, 
such as decreased N- acetyl- aspartate or increased myo- inositol lev-
els, were found in dorsal and ventral areas of the prefrontal cortex in 
PBD.216-224
Although very valuable given the possibility of in vivo mea-
surement of metabolites that might relate to pathophysiologic 
processes of neuronal integrity/viability, glutamatergic neurotrans-
mission, and cell energy metabolism, the exact meaning of these 
results is poorly understood, partly because they are difficult to 
replicate or to predict. For instance, although several proton spec-
troscopy studies reported positive results for specific metabolite 
differences between patients and controls (eg, N- acetyl- aspartate 
or glutamine),215,220,223,224 within the same experiment, results are 
often negative for other metabolites (eg, creatine, myo- inositol and 
choline).215
8.2 | Neuroimaging in relation to treatment
There is a preliminary literature regarding neuroimaging studies in 
relation to treatment of PBD. For instance, an association between 
change in prefrontal glutamate concentrations and change in manic 
symptoms was reported in patients who achieved remission of mania 
after treatment with divalproex sodium.225 Remission of mania after 
olanzapine treatment was associated with an increase in ventrome-
dial prefrontal N- acetyl aspartate and choline levels.226 Quetiapine 
treatment for bipolar depression may lead to decreased neural ac-
tivity in the left occipital cortex, and increased neural activity in the 
left insula, left cerebellum, and right ventrolateral prefrontal cortex 
during performance of a face emotion recognition task.227 Treatment 
of mania with ziprasidone was associated with an increase in activa-
tion in the right ventrolateral prefrontal cortex in response to a sus-
tained attention task, which suggests that the ziprasidone antimanic 
effect is associated with improved prefrontal modulation of emotional 
regulation.228 Carbamazepine treatment of mania was also associated 
with increased activation in Brodmann area 10 of the right prefrontal 
cortex in a small sample of 11 adolescents,229 further suggesting that 
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mood stabilizers might exert their beneficial effects by improving the 
top- down prefrontal modulation of limbic areas. Treatment response 
to risperidone and divalproex sodium for mania may lead to increased 
functional connectivity of the amygdala within the ECN.230 These 
preliminary findings offer insights regarding putative mechanisms 
of action of these medications. One recent study provided evidence 
that some psychotherapy modalities, such as FFT, improve dorsolat-
eral prefrontal cortex activation and decrease amygdala activation 
in youth with mood dysregulation at familial risk for BD,231 which is 
consistent with the putative treatment effects of mood stabilizers (ie, 
improved prefrontal modulation of limbic areas, or better “top- down 
control”). Additional studies are necessary to better understand the 
physiology of treatment response and guide improved therapeutic 
strategies.
8.2.1 | Neurocognition
PBD is associated with impairment in several cognitive domains.232 
A meta- analysis of 10 cognitive studies reported overall cogni-
tive deficits in PBD (n = 352) compared to healthy controls (HCs; 
n = 439) with mean effect sizes that are: large in verbal memory; 
moderate to large in attention and working memory; moderate in 
executive functioning, visual perceptual skills, and visual memory; 
and small to moderate in motor speed, reading achievement, full- 
scale IQ, and verbal fluency.232 A prospective study showed that 
youth with PBD may exhibit a delay in cognitive development 
compared with controls in some cognitive domains (eg, executive 
functioning and verbal memory), despite optimal pharmacologic 
management.233 Thus, it is essential to investigate therapeutic strat-
egies, such as cognitive remediation234 and/or optimizing cardio-
metabolic health,78 that might be useful to restore these cognitive 
deficits and improve academic, social and functional impairments in 
youth with PBD.
In summary, in the last two decades, many neuroimaging and 
cognition studies have demonstrated anomalous brain structure, 
brain function, and cognition, alongside preliminary evidence of 
lagging neurocognitive development in PBD, mainly relating to the 
ECN.
8.3 | Limitations, gaps, and future directions
Further studies are necessary to understand whether abnormal neu-
rodevelopment is present across other brain regions and to what ex-
tent abnormal neurostructure is related to abnormal brain function, 
behavioral aspects of the disease, and alterations in cognitive, social 
and functional development. Essential questions that remain unan-
swered concern how these abnormalities predict clinical course or 
the social, academic, personal, and functional impairments present 
in PBD. Additionally, it is largely unknown which brain abnormali-
ties represent risk factors, resilience factors, early disease markers, 
or some combination of these. Studies that integrate information 
from different imaging modalities and theoretical perspectives should 
help parse these effects. Longitudinal studies will be crucial to help 
to discern developmental and progressive neurophysiological aspects 
of PBD. Finally, future studies need to parse the independent and in-
teractive effects of PBD in relation to treatment effects and response 
markers, as well as common comorbidities such as ADHD, anxiety, 
and substance use disorders.
9  | PERIPHERAL BIOMARKERS
9.1 | Established findings and consensus
Numerous studies over the past decade have examined peripheral 
biomarkers among adults with BD, focusing most consistently on a 
pattern of increased inflammatory and oxidative stress markers and 
decreased neurotrophic markers, particularly during acute mood epi-
sodes.235-238 Peripheral biomarkers, particularly those that fluctuate 
in relation to symptoms, have the potential for clinical application 
such as in the selection, prediction, and assessment of treatments. In 
contrast to the relatively broad literature on neuroimaging and neuro-
cognition, there is a relative dearth of studies on peripheral biomark-
ers among youth with BD. However, in recent years there has been 
growing interest in this topic. Given the nascent literature, the follow-
ing is a synopsis rather than a conclusive demonstration of replicated 
findings.
In a study of 30 adolescents with PBD, hypomanic symptoms were 
associated with levels of high- sensitivity c reactive protein (hsCRP). 
Brain- derived neurotrophic factor (BDNF) and interleukin 6 (IL- 6) were 
negatively associated with each other, and cardiovascular high- risk 
levels of hsCRP were observed in 40% of the sample.239 A subsequent 
larger study on the topic based on 123 young adults in the Course and 
Outcome of Bipolar Youth study found that, controlling for comorbid-
ity and treatment, tumor necrosis factor alpha (TNF- α) was associated 
with the proportion of time with psychosis, IL- 6 was associated with 
the proportion of time with subthreshold mood symptoms and with 
any suicide attempt, and hsCRP was associated with maximum depres-
sion severity over the preceding 6 months.240
Two controlled studies of adolescents with PBD provide support 
for elevated inflammation. The first study (18 BD patients, 13 major 
depressive disorder [MDD] patients and 20 HCs) found significantly 
higher levels of nuclear factor kappa beta (NF- κβ) in peripheral blood 
mononuclear cells, monocytes, and lymphocytes, higher IL- 1β plasma 
levels, and greater TNF- α- induced elevations in NF- κβ in adolescents 
with mood disorders than in HCs.241 The second study (40 BD patients 
and 20 HCs) found elevated IL- 6 and TNF- α levels among adolescents 
with PBD.242
A recent study of 30 adolescents with BD found that oxidative 
stress markers were lower as compared to adults with BD, and lipid 
hydroperoxide (LPH) levels were associated with a proxy measure 
of atherosclerosis but not with mood symptoms or medications.243 
A population- based study of young adults found that those with 
BPSD, but not those with MDD, had increased protein oxidative 
damage compared to HCs.244 A study of adolescents with or at risk 
for PBD found that adolescents with PBD had significantly lower 
LPH vs controls, with non- symptomatic adolescents at familial risk 
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falling between the other groups.245 Finally, a study of 29 adoles-
cents with PBD and 25 HCs found that LPH−BDNF correlations 
were significantly different between adolescents with PBD and 
HCs, and that, among adolescents with PBD in the top half of the 
distribution of BDNF levels, greater LPH levels were associated with 
poorer executive function.246
In an early biomarker study, platelet- derived BDNF protein and 
lymphocyte- derived BDNF mRNA levels were reduced among 26 
medication- free youth with PBD compared to HCs; mRNA BDNF 
levels increased significantly in a subset of 19 participants after 
8 weeks of treatment.247 A study of 30 adolescents with BD found 
a significant association between BDNF levels and amygdala vol-
umes,248 whereas other findings from the same sample indicated 
no association between neurotrophic factors and hippocampal 
volumes.249
Similar to blood- based biomarkers, the literature regarding the 
genetics of PBD is sparse. A family- based association study found 
that genes coding for the serotonin transporter (solute carrier family 
6 member 4), BDNF, and catechol- O- methyltransferase (COMT) were 
not significantly associated with PBD,250 whereas a prior study based 
on the same sample found that four of 28 single nucleotide polymor-
phisms (SNPs) in the dopamine transporter gene (SLC6A3) were as-
sociated with PBD, of which only rs40184 remained significant after 
correction for multiple comparisons.251 Another family- based associ-
ation study found that two SNPs in early growth gene 3 (EGR3) were 
nominally significantly associated with PBD,252 as were glutamate 
decarboxylase 1 (GAD1)253 and BDNF val66 alleles.254 Most recently, 
a genetic study based on participants in the Treatment of Early Age 
Mania study found that a calcium channel, voltage- dependent, L type, 
alpha 1c subunit (CACNA1C) haplotype was associated with PBD. 
Whereas the CACNA1C rs1006737 SNP has been previously associ-
ated with adult BD in genome- wide association studies,255 it was the 
rs10848632 CACNA1C SNP that was nominally associated with PBD 
in SNP analyses.256
9.2 | Limitations, gaps, and future directions
Despite the substantial increase in research findings in this area 
over the past 5 years, important limitations and gaps remain. Most 
studies have been constrained by small samples, limited covariate 
modeling, and cross- sectional design. Ultimately, the clinical applica-
tion of peripheral biomarkers will require that findings are signifi-
cant in the heterogeneous samples in which these biomarkers would 
be employed, as reflected by a variety of comorbidities, different 
subtypes of PBD, and varying medication regimens. Studies using 
repeated measures afford the advantage of within- subject analy-
ses, which mitigate the impact of heterogeneity and state- related 
changes. With regard to genetics, larger studies are needed, as are 
studies examining the link between genetic markers and intermedi-
ate phenotypes, such as neuroimaging, in PBD. In addition to these 
considerations, studies that incorporate biomarkers as objective pre-
dictors, treatment targets, and/or correlates of treatment response 
are warranted.
10  | CONCLUSIONS
There has been substantial progress in the area of PBD over the past 
20 years. As data have accumulated and controversy has dissipated, 
the field has moved past existential questions about PBD toward 
defining and pursuing pressing clinical and scientific priorities that 
remain. The overall body of evidence supports the position that per-
ceptions about marked international and developmental differences 
have been overstated, albeit that additional research on these topics is 
warranted. Traction toward improved outcomes will be supported by 
continued emphasis on phenomenology, prospective clinical epidemi-
ology, pathophysiology, measurement- based quantitative approaches 
including digital phenotyping, and novel therapeutics.
Despite the substantial increase in consensus regarding phe-
nomenology and epidemiology, there remain outstanding questions 
about the prevalence of PBD in pre- pubertal children. Whereas the 
existence of PBD in pre- pubertal children has long been recognized, 
and indeed described in Kraepelin’s seminal text,257 reliable and valid 
estimates of the epidemiologic and clinical prevalence of PBD in pre- 
pubertal children are lacking. With the progress that has been made, in 
terms of parsing PBD from chronic irritability without episodic mania/
hypomania, in terms of increased recognition of PBD, and in terms 
of screening and diagnostic instruments, the field is now better posi-
tioned to examine this topic than it was as recently as a decade ago.
In terms of pathophysiology, it is important to consider the con-
text of the Research Domain Criteria (RDoC) initiative, which suggests 
the value of integrating dimensional liability traits alongside DSM- 
driven diagnoses and diagnostic criteria. In addition to all the inherent 
complexity of BD in adults, including differences across mood states, 
comorbidities, and BD subtypes, among others, research focusing on 
youth includes the added challenge of developmental differences. 
Future research should focus on age effects on the biology, manifesta-
tions, and treatment of PBD.
Future research should also focus on meaningfully integrating 
multiple methodologic levels of analysis. Thus far, there is a paucity 
of research that combines, for example, multiple neuroimaging ap-
proaches, neuroimaging and/or neurocognition with biomarkers, and/
or neurobiology and clinical epidemiology. To the extent that the field 
can apply the large sample sizes and prospective measures of cohort 
studies toward improved understanding of the neurobiology of PBD, 
findings will become increasingly clinically and heuristically relevant.
From a treatment perspective, it will be important to begin ad-
dressing functional outcomes, rather than simply focusing on symp-
tom reduction. Even during recovery, youth with PBD demonstrate 
impaired psychosocial functioning. Improved understanding of the 
factors underlying these impairments will allow for targeted preven-
tive and treatment approaches. More studies with longer periods of 
acute treatment and maintenance studies will both help to clarify sta-
bilization and relapse prevention. Representative epidemiologic, not 
just clinical, PBD samples show very high rates of suicidality and multi- 
comorbidity alongside very low rates of treatment, even though “over- 
treatment” and “over- diagnosis” garner more attention.258,259 The 
high degree of complexity and severity of PBD, even in the relatively 
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early years of the disease, is in part an outcome of delaying or avoid-
ing treatment altogether. It is crucial that the clinical and scientific 
community continues collaborative efforts, together with consumers, 
families, schools, and other stakeholders, toward public education and 
stigma reduction.
Finally, prevention strategies must be an area of emphasis in 
the decade ahead. Findings suggest that some psychotherapies and 
perhaps nutritional interventions might be low- risk options for early 
stage/prodromal intervention. Here, prevention refers not only to the 
prevention of BD, which is an important but relatively distal goal, but 
also to the prevention of comorbidity accumulation (eg, substance use 
disorders), suicidality, treatment refractoriness, neurocognitive and 
functional impairment, and adverse physical health outcomes. Indeed, 
the physical implications of BD, particularly in terms of future cardio-
vascular disease, are increasingly recognized.79 Just as it is important 
for primary care providers to recognize the increased cardiovascular 
risk associated with PBD, it is important for our own field to begin in-
tegrating brain−body considerations in the assessment and treatment 
of PBD. The therapeutic and preventive potential of physical exercise 
for PBD, for example, is an almost entirely untouched topic.260,261
While many questions remain unanswered, or insufficiently an-
swered, we are hopeful that progress over the next decade will be far 
less constrained by controversies that, although critical in defining the 
directions of the field, also slowed progress and limited collaboration. 
At a time when clinically relevant psychiatric research faces the iron-
ically dichotomous pressures of the RDoC era (ie, choosing between 
DSM and RDoC), it is important to retain focus on the importance of 
the categorical BD diagnosis in terms of treatment selection, clinical 
course, and familial risk. We are optimistic that liberally applied inte-
gration strategies (ie, dimensional as well as categorical views, neuro-
biology alongside clinical epidemiology, and pharmacologic alongside 
psychosocial interventions) will best serve the needs of our field and 
our constituents.
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